Drugs & OTC

Anatara Lifesciences Ltd (ASX:ANR) Market Update

🕔4/7/2021 10:34:56 AM

Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara's human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Completion of Unmarketable Parcel Share Buy-Back

🕔2/10/2021 8:51:29 AM

On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives Ethics Approval to Start IBS Trial

🕔2/8/2021 9:42:00 AM

Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) R&D Tax Incentive Received

🕔2/3/2021 9:33:37 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $888,049 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Successful Poultry Trial

🕔2/1/2021 8:52:29 AM

Anatara Lifesciences (ASX:ANR) is pleased to announce successful completion of the poultry challenge trial "Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Cash Report

🕔1/28/2021 10:13:28 AM

Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2020. The Company's cash plus term deposits at the end of the quarter stood at $3.68m.

Read Full Article

Nyrada Inc (ASX:NYR) 57% Reduction in Total Cholesterol from Nyrada's NYX-PCSK9i In Vivo Study

🕔12/21/2020 10:20:51 AM

Nyrada Inc (ASX:NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholesterolemia (high cholesterol).

Read Full Article